1. Study design (A) and patient disposition (B).
Study design (A) and patient disposition (B). (A) *Patients received 2,000 or 1,500 mg/day according to tolerability. (B) Patients discontinued at week 26 are also included as discontinued at week 52. aNumber of patients rescued at week 26 for severe, persistent hyperglycemia: dulaglutide 1.5 mg, 6 (2.2%); dulaglutide 0.75 mg, 6 (2.2%); and metformin, 7 (2.6%). bNumber of patients rescued at week 52 for severe, persistent hyperglycemia: dulaglutide 1.5 mg, 12 (4.5%); dulaglutide 0.75 mg, 8 (3.0%); and metformin, 14 (5.2%). BID, twice daily.
Guillermo Umpierrez et al. Dia Care 2014;37:
©2014 by American Diabetes Association